Apexigen, Inc. (APGN)

Overview

Apexigen Inc., founded in 2010 and located in San Carlos, California, is a clinical-stage biotechnology firm focused on the development and discovery of innovative antibody-based therapies targeted at oncological diseases. The company is in the advancement phase of several leading therapeutic candidates within its developmental pipeline, showcasing a commitment to addressing critical unmet medical needs in cancer treatment. A significant component of their research is centered around APX005M, a humanized agonist antibody currently undergoing Phase II clinical trials, assessing its effectiveness against a range of solid tumors. These tumors include melanoma, esophageal cancer, sarcoma, and malignancies affecting the rectal and ovarian regions. The company often employs APX005M in combination with standard treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines to enhance therapeutic outcomes. Furthermore, Apexigen is actively advancing APX601, a humanized antagonist antibody, which is in Phase I/II clinical trials for multiple tumor indications. The company continues to innovate with its experimental pipeline that includes APX801, an NK cell engager designed to reactivate natural killer cells to target and eliminate cancer cells.

Products and Services

• APX005M

  This humanized agonist antibody is currently in Phase II clinical trials, being studied for its potential to treat various solid tumors, including melanoma and certain cancers of the esophagus, rectum, sarcoma, and ovarian cancers. It is uniquely positioned to function synergistically with established therapeutic modalities such as immunotherapy and chemotherapy.

• APX601

  A humanized antagonist antibody in Phase I/II clinical trials, APX601 is designed to target numerous tumor indications. It aims to inhibit tumor growth and enhance the overall effectiveness of cancer treatment regimens by acting on specific immune pathways.

• APX801

  This innovative NK cell engager is engineered to stimulate the body’s natural killer (NK) cells, encouraging them to seek out and destroy cancerous cells. With its focus on harnessing the body's own immune response, APX801 has the potential to be a transformative approach in the field of immuno-oncology.